uploads/2018/10/headache-1540220_1920.jpg

Analyzing Pfizer’s Stock Performance in October

By

Updated

About Pfizer

Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.

The above chart compares Pfizer’s stock performance with its peers in October.

Article continues below advertisement

Pfizer’s stock performance

So far, Pfizer’s stock price has increased ~1.1% in October. The company’s stock price increased nearly 3.6% during the past month.

Pfizer also reported 23.1% growth in its stock price in the last 12 months and 23.0% growth in its stock price in 2018.

However, analysts’ estimates show that the stock might decrease ~3.7% over the next 12 months. Analysts’ recommendations show a 12-month target price of $42.94 per share—compared to the last price of $44.57 per share as of October 17.

Peers’ stock performance

Pfizer’s peers include pharmaceutical companies like Johnson & Johnson (JNJ), Merck (MRK), and Eli Lilly (LLY).

Johnson & Johnson’s stock price has increased ~0.9% in October. The stock price decreased nearly 0.4% in the past month. Merck’s stock price has increased ~1.2% in October. The stock price increased nearly 2.0% in the past month. Eli Lilly’s stock price has increased ~5.9% in October. The stock price increased nearly 7.5% in the past month.

Notably, the First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 8.8% of its total investments in Pfizer, 6.8% in Johnson & Johnson, 4.3% in Merck, and 8.2% in Eli Lilly.

Advertisement

More From Market Realist